Pharma & Cancer Treatment 2025: Breakthroughs, Market Leaders, and Industry Trends

By Editorial Team -
The landscape of cancer treatment and the pharmaceutical industry is undergoing rapid transformation in 2025, driven by scientific breakthroughs, shifting drug sales rankings, and evolving strategies among top pharma companies. This article synthesizes the latest advances in cancer therapy, highlights the world’s top-selling drugs, and examines the leading pharmaceutical players shaping the future of oncology and global health.

Pharma & Cancer Treatment: Breakthroughs, Market Leaders, and Industry Trends (2025)

Latest Breakthroughs in Cancer Treatment (2025)

The fight against cancer is being reshaped by a wave of innovations, many of which are already impacting clinical practice or are in advanced stages of development:

Next-Generation Immunotherapy

New checkpoint inhibitors, CAR-T cell therapies, and bispecific antibodies are expanding options for hard-to-treat cancers such as pancreatic and brain tumors.

Related: Combining Repurposed Drugs with Immunotherapy: A Novel Approach to Cancer Treatment

AI-Based Risk Profiling

AI and machine learning are being used for early cancer detection and risk assessment, particularly in regions with limited access to imaging specialists.

CRISPR Gene Editing

Clinical trials are leveraging CRISPR to edit genes within cancer or immune cells, aiming to correct mutations and enhance immune targeting of tumors.

Related: First-in-Human Trial of CRISPR Gene Therapy for HIV (Medscape 2024)

AI-Driven Drug Discovery

Artificial intelligence is accelerating the identification of new cancer drugs, cutting development time and uncovering novel treatment avenues.

Tumor Microenvironment Targeting

Drugs that alter the tumor’s surrounding environment are being developed to enhance the effectiveness of existing therapies.

Repurposed Drugs: Unlocking New Potential in Alternative Cancer Treatment

A significant breakthrough in 2025 is the growing use of repurposed drugs as alternative cancer treatments—medications originally developed for non-cancer conditions but now showing promise in oncology. Drugs like ivermectin, mebendazole, and fenbendazole, traditionally used as antiparasitic agents, are being studied for their anticancer properties. A peer-reviewed protocol published in September 2024, led by researchers such as Dr. Ilyes Baghli and Dr. Paul Marik, demonstrates that these drugs can disrupt cancer cell growth by targeting microtubules, essential for cell division [Baghli et al 2024].

A significant breakthrough in 2025 is the growing use of repurposed drugs—medications originally developed for non-cancer conditions but now showing promise in oncology. Drugs like ivermectin, mebendazole, and fenbendazole, traditionally used as antiparasitic agents, are being studied for their anticancer properties. A peer-reviewed protocol published in September 2024, led by researchers such as Dr. Ilyes Baghli and Dr. Paul Marik, demonstrates that these drugs can disrupt cancer cell growth by targeting microtubules, essential structures for cell division. When used in combination, they exhibit a synergistic effect, offering a potent, affordable treatment option [Baghli et al 2024].

Additionally, drugs like metformin, originally developed for diabetes, and anastrozole, a breast cancer treatment now repurposed for prevention, are gaining traction. Metformin disrupts cancer cell metabolism, while anastrozole reduces estrogen levels to lower breast cancer risk. These repurposed drugs are particularly valuable in low- and middle-income countries, where access to expensive therapies is limited, and their established safety profiles accelerate their integration into clinical practice.

References:
While anecdotal reports, such as 180 case studies on fenbendazole, suggest benefits, controlled clinical trials are needed to confirm efficacy. Patients considering these treatments should consult integrative oncologists to tailor protocols to their needs.

Liquid Biopsies

Non-invasive blood tests for early cancer detection and monitoring are becoming more refined and accessible.

Gut Microbiome Research

The gut microbiome’s influence on immunotherapy efficacy is under investigation, with personalized probiotics being explored as adjuncts to cancer treatment.

AI-Assisted Radiotherapy

AI is making radiotherapy more precise, reducing collateral damage to healthy tissue.

Holistic and Integrative Approaches

Complementary therapies, including dietary interventions and lifestyle changes, are increasingly incorporated into cancer care.

CAR-T Cell Therapy

Long-term remission in leukemia patients has been achieved, but concerns remain about potential secondary cancers, prompting regulatory scrutiny.

Pancreatic Cancer Advances

Early detection tests and new insights into the disease’s molecular mechanisms are offering hope for one of the deadliest cancer types.

Personalized Cancer Vaccines

mRNA-based vaccines are now tailored to individual tumors, training the immune system to recognize and attack cancer cells. Trials in the UK and Europe are underway, with hopes of fewer side effects and reduced recurrence compared to traditional chemotherapy.

Top 10 Drugs by Worldwide Sales in 2024 (Updated for 2025)

The global pharmaceutical market in 2025 continues to be dominated by a mix of oncology immunotherapies, metabolic drugs, and treatments for autoimmune diseases. The latest forecasts and sales data reveal significant growth in cancer immunotherapy led by Merck’s Keytruda, alongside the rising prominence of GLP-1 receptor agonists for diabetes and weight management.

Key Highlights:

  • Keytruda (Pembrolizumab) remains the world’s bestselling drug, with sales projected to exceed $31 billion in 2025. Its growth is driven by continuous expansion of approved indications, now totaling around 40 worldwide, including recent approvals for cervical cancer and other malignancies. Merck reported an 18% year-on-year sales increase in the first three quarters of 2024, underscoring its dominant position in oncology.

  • GLP-1 receptor agonists dominate metabolic therapy sales, with Novo Nordisk’s Ozempic (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) ranking second and third, generating $21 billion and $19 billion respectively. These drugs target type 2 diabetes and obesity, reflecting growing global demand for effective metabolic disease treatments.

  • Dupixent (dupilumab) and Skyrizi (risankizumab) continue to lead in autoimmune disease treatment, maintaining strong sales above $13 billion each, driven by expanding indications in dermatology and inflammatory diseases.

  • Other oncology drugs such as Darzalex (daratumumab) and Opdivo (nivolumab) hold significant positions, with Darzalex generating around $13 billion in revenue and Opdivo also maintaining multi-billion dollar sales.

  • Biktarvy, an antiretroviral for HIV, and Eliquis, an anticoagulant, continue to be among the top sellers, each with approximately $13 billion in sales.

  • Wegovy, another semaglutide-based drug for chronic weight management, has surged to fifth place with $14.3 billion in sales, highlighting the expanding market for obesity treatments.

Market Trends:

  • Four of the top ten drugs belong to the GLP-1 class (semaglutide and tirzepatide variants), underscoring the blockbuster status of metabolic therapies.

  • Immuno-oncology remains a cornerstone of pharma growth, with Keytruda’s sustained leadership and Opdivo’s continued presence.

  • Autoimmune therapies maintain strong demand with Dupixent and Skyrizi.

  • The pharmaceutical market is increasingly shaped by combination therapies, expanded indications, and innovative delivery systems.

Pharma Industry Leaders: R&D and Oncology Focus

The pharmaceutical industry’s biggest players are investing heavily in research and development, particularly in oncology:

  • Merck & Co. leads with Keytruda, the world’s top-selling cancer drug, and is actively pursuing new indications and combination regimens.

  • Novo Nordisk has transformed the obesity and diabetes market with Ozempic and Wegovy, signaling a shift toward metabolic disease as a major growth area.

  • AbbVie, despite biosimilar competition for Humira, remains a top player through diversification and pipeline development.

  • Bristol Myers Squibb (BMS) and Pfizer continue to dominate in cardiovascular, oncology, and immunology segments.

Trends Shaping the Future of Cancer and Pharma

  • Personalization and Precision: From vaccines to gene editing, therapies are increasingly tailored to individual patients’ genetic and molecular profiles.

  • AI and Digital Health: Artificial intelligence is transforming everything from drug discovery to diagnostics and treatment planning.

  • Repurposing and Combination Therapies: Old drugs are finding new life in oncology, often in combination with cutting-edge treatments.

  • Global Access and Equity: Efforts are underway to make advanced therapies more accessible worldwide, with clinical trials expanding beyond traditional markets.

  • Regulatory and Safety Challenges: The rapid pace of innovation brings new safety and regulatory considerations, as seen with CAR-T therapy’s potential risks.

Conclusion

2025 marks a pivotal year in cancer treatment and the pharmaceutical industry. Breakthroughs in personalized medicine, gene editing, and AI are converging with market shifts driven by blockbuster drugs and strategic R&D investments. As the world’s leading pharma companies race to bring new therapies to market, patients stand to benefit from more effective, targeted, and accessible treatments than ever before.


Sources and References:

Comments

Post a Comment

Pages

Popular posts from this blog

Top 10 Drugs by Worldwide Sales in 2024

By Editorial Team -
Image
It's been several years since COVID-19 vaccines from Pfizer and Moderna jumped to the top of the pharma industry's sales charts, displacing longtime stalwarts with unprecedented sales. But, as 2023 featured major patent expirations, the rise of weight loss drugs and other new dynamics, the year’s ranking of the top 10 drugs by global sales featured its fair share of surprises. Merck’s oncology king Keytruda rose to the top last year, adding yet another feather in its cap. With more than 30 indications across various cancer types and stages, the PD-L1 inhibitor shows no signs of stopping. With $25 billion in global sales, the drug accounted for about 40% of Merck’s total revenue last year. Keytruda's sales are expected to reach $30 billion this year. Keytruda had previously fallen right behind AbbVie's Humira, which held the title of the world’s bestselling drug for nine years in a row until Pfizer and BioNTech’s Comirnaty knocked AbbVie’s Humira off its perch in 2021. N...
Read more

Top 10 Pharmaceutical Companies by Revenue in 2025

By Editorial Team -
Image
Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Lilly—boosted by sales of its diabetes and obesity drugs Moujaro and Zepbound— projects  its sales to fall between $58 billion and $61 billion. At the midpoint of the projection, it would be a 32% increase, matching the sales boom it saw last year. Meanwhile, Novo—which also has been powered by sales of its diabetes and obesity treatm...
Read more

7 Best Crypto Exchanges Malaysia 2025

By Editorial Team -
Image
If you're looking for the best cryptocurrency exchanges in Malaysia in 2025, it's important to choose platforms that are secure and fully compliant with local regulations. In Malaysia, Digital Asset Exchanges (DAX) are regulated and licensed by the Securities Commission Malaysia (SC), which ensures they meet strict standards for investor protection and legal compliance. Luno, Binance, Sinegy, Tokenize Exchange, MX Global, Hata and Torum are popular choices. The best cryptocurrency exchanges work similarly to the best stock trading apps, offering competitive fees and resources on digital marketplaces like mobile or desktop. Crypto enthusiasts can easily buy, sell, and store popular digital currencies like Bitcoin or altcoins like Ethereum. Note that if you don't want to use your exchange's built-in wallet (if applicable), you'll need to set up an external crypto wallet, to store your assets securely. Here are details of cryptocurrency exchanges you can use to buy Bit...
Read more

5 Top Silver ETFs 2025: What You Need to Know

By Editorial Team -
Image
Along with gold, silver is in high demand as precious metals are highly sought after as safe havens in uncertain economic environments, boosting prices and assets for top silver ETFs like the iShares Silver Trust (SLV). Investors use silver ETFs for various purposes. Other than its safe-haven benefits, some invest for speculative reasons, hoping to profit from potential increases in silver prices or as a hedge against geopolitical turmoil or currency devaluation. Keep reading to learn more about investing in silver and see a list of top ETFs investing in the precious metal.   What Are Silver ETFs?  Silver ETFs are exchange-traded funds that provide exposure to the price of silver, a precious metal. These ETFs are designed to track the performance of silver prices, making it easier for investors to gain exposure to the silver market without physically owning and storing the metal itself. Silver's unique combination of properties, including its electrical conductivity, thermal c...
Read more

Top 10 Pharma Companies by R&D Spend 2024

By Editorial Team -
Image
In 2024, the pharmaceutical industry witnessed significant shifts in research and development (R&D) investments, with companies like Merck & Co. and AstraZeneca making notable strategic decisions that impacted their positions among top R&D spenders. The average cost for major pharmaceutical companies to develop a drug in 2024 rose to $2.23 billion, up from $2.12 billion the previous year. This increase reflects the growing complexity and expense associated with bringing new therapies to market. ​( Fierce Biotech ) These developments illustrate the dynamic nature of R&D investments in the pharmaceutical sector, influenced by strategic partnerships, acquisitions, and the escalating costs of drug development. 1. Merck & Co. R&D SPENDING 2024: $17.9 billion Change from 2023: -41% Total 2024 revenue: $64.2 billion R&D budget as percentage of revenue: 28% Market capitalisation: 198.3 B USD (as of June 2025) Merck & Co.’s R&D spending plummeted from the d...
Read more

Bitcoin Nasdaq Correlation: The Correlation between the Nasdaq index and Cryptocurrencies 2025

By Editorial Team -
Image
The correlation between the Nasdaq index and cryptocurrencies, particularly Bitcoin, has been a subject of interest and analysis, reflecting the increasing integration of digital assets into the broader financial ecosystem. Here's a detailed look at this relationship: Historical Context and Trends: Increasing Correlation : Over the past few years, there has been a noticeable trend towards a stronger correlation between Bitcoin and the Nasdaq Composite Index, especially with tech-heavy indices like the Nasdaq 100. As of early 2025, this correlation has been observed to be at a high level, with some periods showing a correlation coefficient above 0.9. This suggests that movements in Bitcoin prices often mirror those of the Nasdaq, particularly during bullish market phases for tech stocks. Institutional Influence : The growing involvement of institutional investors in cryptocurrencies has played a significant role in this correlation. Companies like Coinbase, which has a listing on Na...
Read more

10 Best E Wallets in Malaysia 2025

By Editorial Team -
Image
An e-wallet or a digital wallet is a feature within an app that allows transactions to be made via a smartphone. Similar to a traditional 'wallet', the e-wallet stores digital cash instead of physical cash. The prominence of e-wallets in Malaysia has grown significantly in the past few years, with its huge growth mainly driven by the government’s efforts and active marketing efforts by various companies. Credit: CompareHero.my Let’s check out the popular eWallets in Malaysia now with their payment method, top up method and other features as below: 1) E Wallet Touch 'n GO Malaysia Courtesy of tngdigital.com.my TouchnGO eWallet is owned by TNG Digital Sdn Bhd, It’s an all in one e-wallet service covering all existing and future Touch ‘n Go products & services, with the Slogan “Shaping the future of e-payments for Malaysians”. Payment Method : QR Code Transfer to Friends : Yes, with Phone Number Top Up Method : FPX, Credit or Debit Card, Reload Pin, or Auto Reload Merchant...
Read more

12 Best SME Business Loans in Malaysia 2025

By Editorial Team -
Image
Several banks in Malaysia offer business loans tailored for SMEs. Maybank and CIMB are popular choices, offering a variety of loan amounts and competitive interest rates. Other notable options include Public Bank and RHB, while SME Bank and MIDF also provide dedicated financing solutions for small and medium-sized enterprises.   SME or also known as Small and Medium-sized Enterprises are businesses that maintain revenues, assets, or a number of employees below a certain threshold. These business entities are often regarded as the heartbeat of Malaysia’s emerging and developing economies. Apart from providing vast numbers of employment opportunities, SME businesses are generally entrepreneurial in nature, helping to shape innovation. Generally, there are two criteria to be met in order for your business to qualify as an SME -- your annual sales turnover and the number of full time employees in your company. This also implies differently for each economy sector: Manufacturing (S...
Read more

Top 10 Drugs by Worldwide Sales in 2025

By Editorial Team -
Image
The pharmaceutical market in 2025 continues to be led by innovative therapies addressing cancer, metabolic diseases, autoimmune conditions, and chronic illnesses. Below is an updated overview of the top 10 drugs by projected global sales in 2025. Highlights and Market Trends Keytruda (Pembrolizumab) remains the global leader in drug sales with projected revenues exceeding $31 billion in 2025. This cancer immunotherapy has expanded to over 40 approved indications since its launch in 2014, including multiple cancer types, driving strong sales growth. Merck reported $21.6 billion in sales for the first three quarters of 2024, an 18% increase year-on-year ( 2 ,  5 ,  7 ) . GLP-1 receptor agonists dominate the metabolic therapy segment with four drugs in the top 10: Ozempic and Wegovy (both semaglutide-based), Mounjaro and Zepbound (tirzepatide-based). These drugs are primarily used for type 2 diabetes and obesity management, reflecting the growing global focus on metabolic di...
Read more